Oncocyte Corp. Engages at the Needham Virtual Healthcare Conference
IRVINE, Calif. — Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology firm, has announced that its Chief Executive Officer, Josh Riggs, alongside Chief Financial Officer Andrea James, will participate in the 24th Annual Needham Virtual Healthcare Conference. This key event will occur from April 7-10, providing a platform for innovative ideas and breakthroughs in healthcare technology.
Preview of Key Highlights at the Conference
During the conference, both Josh and Andrea are set to lead discussions around Oncocyte’s cutting-edge diagnostic technologies. The spotlight will be on their ambitious goals in commercializing a regulated organ transplant rejection monitoring test kit. By leveraging a market-disruptive strategy, Oncocyte aims to position itself at the forefront of transforming transplant monitoring.
Discussion Points
At the event, attendees can look forward to insights on how Oncocyte’s advanced solutions are becoming crucial tools for healthcare professionals. The company’s focus on enhancing patient outcomes through accurate diagnosis sets it apart in the diagnostics sector.
Engagement Opportunities for Interested Investors
Investors eager to engage with Oncocyte can attend the virtual fireside chat or arrange for one-on-one meetings by contacting their Needham sales representative. Such interactions provide a unique opportunity for discussions about the company’s vision and upcoming projects.
About Oncocyte's Innovations
Oncocyte is recognized for its diagnostic technology products, which aim to provide clarity and confidence to physicians and their patients. Their flagship product, VitaGraft™, serves as a clinical blood-based testing solution designed for solid organ transplantation monitoring. Meanwhile, GraftAssure™ focuses on research for similar applications, while DetermaIO™ delves into gene expression to predict responses to immunotherapies. Additionally, DetermaCNI™ assists in monitoring therapeutic efficacy for cancer patients, showcasing Oncocyte's commitment to advancing diagnostic capabilities across various medical landscapes.
Explore Oncocyte's Product Range
To learn more about Oncocyte's offerings, you can explore:
- VitaGraft Kidney™: https://oncocyte.com/vitagraft-kidney/
- VitaGraft Liver™: https://oncocyte.com/vitagraft-liver/
- GraftAssure™: https://oncocyte.com/graftassure/
- DetermaIO™: https://oncocyte.com/determa-io/
- DetermaCNI™: https://oncocyte.com/determa-cni/
Oncocyte’s Commitment to Excellence
With trademarks like VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™, Oncocyte Corporation exemplifies dedication to enhancing healthcare through technology. Their innovations reflect a deep understanding of the challenges faced in transplant medicine and cancer treatment, which they are actively addressing through their products.
Frequently Asked Questions
What is the focus of Oncocyte Corp. at the Needham Conference?
Oncocyte Corp. will discuss its innovative diagnostic technologies aimed at advancing organ transplant monitoring solutions.
Who will represent Oncocyte at the event?
CEO Josh Riggs and CFO Andrea James will represent Oncocyte at the Needham Virtual Healthcare Conference.
How can investors participate in the conference?
Investors can attend the virtual fireside chat or schedule one-on-one meetings through their Needham sales representative.
What products does Oncocyte offer?
Oncocyte offers several products including VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ aimed at monitoring organ transplants and assessing treatment efficacy in oncology.
What is the significance of Oncocyte's innovations?
Oncocyte's innovations are designed to provide accurate diagnostic solutions that enhance patient care and improve outcomes in organ transplantation and cancer therapy.
